Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Large Growth in Short Interest

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 360,790 shares, an increase of 183.4% from the August 31st total of 127,301 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 590,511 shares, the days-to-cover ratio is presently 0.6 days.

Bayer Aktiengesellschaft Stock Up 1.3%

OTCMKTS:BAYRY traded up $0.18 during midday trading on Monday, reaching $14.50. 309,352 shares of the stock traded hands, compared to its average volume of 1,119,671. The stock has a market capitalization of $56.98 billion, a PE ratio of -28.43, a price-to-earnings-growth ratio of 2.15 and a beta of 0.56. Bayer Aktiengesellschaft has a 12-month low of $7.48 and a 12-month high of $15.23. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The business has a 50-day moving average of $14.00 and a two-hundred day moving average of $12.45.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The business had revenue of $12.53 billion for the quarter, compared to analyst estimates of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, equities analysts forecast that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

BAYRY has been the subject of a number of analyst reports. Zacks Research upgraded Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a report on Friday, July 10th. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research report on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863, the company develops and markets products in healthcare and agriculture and serves customers in markets around the world. Bayer’s American depositary shares trade over the counter under the symbol BAYRY.

The company operates through three principal areas: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals business develops prescription medicines in areas such as cardiovascular disease, women’s health, oncology, neurology and specialty therapeutics.